Pancreatic Cancer Research

ResearcherWuhan Union HospitalNo recent work listed

Zhiqiang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2800-8277; OpenAlex author ID A5100415120. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers

Papers 10

  1. SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis. Co-author DOI 10.1016/j.canlet.2021.07.035↗
  2. COL11A1 is the Key Target Gene of MIST1 on Tumor Progression of Pancreatic Cancer First author DOI 10.21203/rs.3.rs-793040/v1↗
  3. Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway. Co-author DOI 10.1016/j.omto.2020.03.006↗
  4. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biocel.2019.01.011↗
  5. Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis. Co-author DOI 10.1186/s12876-019-0975-3↗
  6. Overexpression of MIST1 reverses the epithelial-mesenchymal transition and reduces the tumorigenicity of pancreatic cancer cells via the Snail/E-cadherin pathw… Co-author DOI 10.1016/j.canlet.2018.05.043↗
  7. Impact of age on survival of patients with pancreatic cancer after surgery: Analysis of SEER data. First author DOI 10.1016/j.pan.2017.11.008↗
  8. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Co-author DOI 10.1038/s41598-017-06207-x↗
  9. Implantation of radioactive (125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study. First author DOI 10.1007/s11596-016-1567-x↗
  10. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Co-author DOI 10.18632/oncotarget.7482↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shanmiao Gou · 7 shared papers, 2016–2021 · strength 0.70
  2. Heshui Wu · 6 shared papers, 2016–2021 · strength 0.61
  3. Chunyou Wang · 5 shared papers, 2016–2018 · strength 0.42
  4. Xiaogang Li · 4 shared papers, 2017–2020 · strength 0.42
  5. Shihong Wu · 3 shared papers, 2019–2020 · strength 0.33
  6. Dianyun Ren · 2 shared papers, 2021 · strength 0.31
  7. Xin Jin · 2 shared papers, 2019–2021 · strength 0.24
  8. Jingyuan Zhao · 2 shared papers, 2019–2020 · strength 0.22
  9. Zibo Meng · 2 shared papers, 2019 · strength 0.21
  10. Ye Zeng · 2 shared papers, 2018 · strength 0.20
  11. Yang Li · 1 shared paper, 2021 · strength 0.16
  12. Yan Sun · 1 shared paper, 2021 · strength 0.15
  13. Yongfeng Li · 2 shared papers, 2016 · strength 0.13
  14. Bo Wang · 1 shared paper, 2019 · strength 0.09
  15. Chong Yang · 1 shared paper, 2019 · strength 0.09
  16. Ping Fan · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.